Analysis of Monoclonal Antibody Digests with the Agilent 1290 Infinity 2D-LC Solution Part 2: HILIC × RPLC-MS

Importance of the Topic

High resolution peptide mapping is vital for in-depth characterization of monoclonal antibodies like trastuzumab. Complex tryptic digests yield >100 peptides, requiring enhanced peak capacity to detect modifications and impurities in biotherapeutic analysis.

Study Objectives and Overview

The application note demonstrates an online comprehensive two-dimensional LC (LC×LC) combining HILIC and reversed-phase LC (RPLC) using the Agilent 1290 Infinity 2D-LC Solution coupled to a 6530 Q-TOF MS. Key goals include improving separation orthogonality, peak capacity, and reliable identification of peptide modifications under stress conditions.

Methodology and Instrumentation

Sample Preparation:

• Tryptic digestion of trastuzumab with reduction, alkylation, and cleanup.
• Forced degradation: oxidation (tert-butyl hydroperoxide) and pH stress.

Chromatographic Setup:

• First dimension: HILIC column (ZORBAX RRHD 300-HILIC, 2.1×100 mm, 1.8 μm), gradient of ammonium formate/acetonitrile at 50 μL/min, 30 °C.
• Second dimension: RPLC column (ZORBAX Eclipse Plus C18, 4.6×50 mm, 3.5 μm), high-speed gradient at 4 mL/min, 30 °C.
• Modulation: 0.45 min cycle with dual 40 μL loops, selective transfer (12–69 min).
• MS detection: Agilent 6530 Accurate-Mass Q-TOF, positive ESI, Jet Stream, high resolution (10,000 at m/z 1000).

Main Results and Discussion

The LC×LC contour map resolved over 60 identity peptides, revealing orthogonal retention of peptides. MS total ion chromatograms enabled precise mass identification (<5 ppm) of modifications such as methionine oxidation and asparagine deamidation. HILIC separation isolated deamidated peptides indistinguishable in RPLC, demonstrating enhanced impurity detection.

Benefits and Practical Applications

• High peak capacity and orthogonal selectivity for complex digest analysis.
• Comprehensive detection of low-level modifications and impurities.
• Online 2D-LC workflow improves throughput compared to offline methods.

Future Trends and Applications

Advances may include integration of additional separation modalities (e.g., ion exchange), automation of 2D-LC methods, and deeper proteoform mapping. Coupling with advanced data analytics and machine learning can further enhance characterization of biotherapeutics.

Conclusion

The Agilent 1290 Infinity 2D-LC Solution combined with Q-TOF MS provides a robust platform for detailed peptide mapping of monoclonal antibodies. HILIC×RPLC–MS offers improved orthogonality and sensitivity for detecting degradation products and modifications, supporting quality control in biopharmaceutical development.

Reference

• Sandra K. et al. LCGC Europe 2013.
• François I. et al. Anal. Chim. Acta 2009.
• Sandra K. et al. J. Chromatogr. B 2009.
• Zhu A. et al. Agilent Application Note 2013.
• D’Attoma A. & Heinisch S. J. Chromatogr. A 2013.
• Vanhoenacker G. et al. Agilent Application Note 2013.